You are not logged in.
Please login to continue selecting trials.
Generic NameSelexipagProduct NameUPTRAVI®Therapeutic AreaHeart and Blood DiseasesEnrollment1156% Female79.8%% White65%
Product ClassProstacyclin receptor agonistSponsor Protocol NumberAC-065A302Data PartnerJohnson & JohnsonCondition StudiedHypertension, Pulmonary, ArterialMean/Median Age (Years)48.1
- Collected Datasets Available
- Data Definition Specification Available
- Protocol with Amendments Available
- Statistical Analysis Plan Available
- Clinical Study Report Available
Approved Data Requests Associated with this Trial
- Predictive Value of QT Interval Dispersion in Patients with Pulmonary Arterial Hypertension (PAH)
- Development and assessment of Virtual Cohorts derived from historical Pulmonary Arterial Hypertension clinical trials.
- Derivation and Validation of Predictive Models in an aggregated Pulmonary Arterial Hypertension cohort